Remove 2024 Remove Ablation Remove Atrial Fibrillation
article thumbnail

Case Report: Fatal atrioesophageal fistula following atrial fibrillation ablation—critical reflections on prevention

Frontiers in Cardiovascular Medicine

Radiofrequency ablation (RFA) is an important therapeutic modality for atrial fibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. A 71-year-old male admitted to the emergency department on July 19, 2024, with acute loss of consciousness and convulsions.

article thumbnail

Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say

DAIC

Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. ERAT is often attributed to transient inflammation induced by tissue damage during ablation and short-term imbalances in autonomic innervation.

article thumbnail

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

DAIC

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.

article thumbnail

Pulsed field ablation for atrial fibrillation: a comprehensive bibliometric analysis of research trends and emerging Frontiers

Frontiers in Cardiovascular Medicine

BackgroundAtrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, posing significant health burdens. Pulsed field ablation (PFA) is an emerging non-thermal technique that is gaining traction due to the ability to selectively target myocardial cells and minimize damage to surrounding tissues.

article thumbnail

CardioFocus to Present Data Supporting Next Generation Pulsed Field Ablation Systems at Heart Rhythm 2024

DAIC

milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.

article thumbnail

QTc interval prolongation and risk of atrial fibrillation recurrence: a meta-analysis and observational cohort study

Frontiers in Cardiovascular Medicine

Previous studies evaluated its value in predicting atrial fibrillation (AF) occurrence. However, its predictive efficacy for AF recurrence remains controversial.MethodsWe searched PubMed and Google databases for studies before January 2024 evaluating the association between QTc interval and AF incidence.

article thumbnail

Cortex Announces RESOLVE-AF Trial Evaluating Electrographic Flow (EGF) Mapping for use in Atrial Fibrillation Ablation

DAIC

Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. By guiding ablation therapy, [EGF mapping] can enable clinicians to provide personalized, highly targeted treatment."

Ablation 104